Table 1.
Baseline characteristics of 31 participants with early diabetic kidney disease in the IMPROVE trial
| Characteristics | n=31 |
|---|---|
| General characteristics | |
| Age, yr | 62 (8) |
| Sex (n, female/male) | 7/24 |
| HbA1c, % | 7.3 (2.9) |
| Diabetes duration, yr | 10 (7) |
| Systolic BP, mm Hg | 143 (15) |
| Diastolic BP, mm Hg | 77 (6) |
| Weight, kg | 94 (22) |
| Body mass index, kg/m2 | 31 (5.6) |
| eGFR, ml/min per 1.73 m2 | 72 (19) |
| 24-h urine albumin excretion, mg/24 ha | 521 (234–997) |
| Markers of bone and mineral metabolism | |
| Serum phosphate, mg/dl | 3.3 (0.6) |
| Serum calcium, mg/dl | 9.4 (0.4) |
| Serum PTH, pg/mla | 45 (35–64) |
| Plasma FGF23, RU/mla | 104 (84–166) |
| Plasma 25(OH)D, ng/ml | 18 (8) |
| Plasma 1,25(OH)2D, pg/ml | 31 (25–39) |
Data are given mean (SD), except where indicated. HbA1c, glycosylated hemoglobin; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
a
Data given as median (interquartile range).